Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03352739 : Fornix and NbM as Targets of Stimulation In Alzheimer's Disease
AgesMin: 45 Years Max: 75 Years
Inclusion Criteria:

1. Subjects with informed consent;

2. 45-75 years of age;

3. At least 6 years of education;

4. AD according to the National Institute on Aging and the Alzheimer's Association
(NIA-AA) guidelines (McKhann et al., 2011);

5. Clinical Dementia Rating Scale (CDR): 1.0-2.0;

6. Positive findings with amyloid PET imaging;

7. Stable prescription of donepezil (5mg, qd) for at least 3 months, and without any
intentions to modify the dosage during the observation period.

Exclusion Criteria:

1. Fazekas scale>2;

2. Neuropsychiatric inventory (NPI) total score ?10, or any subdomain?4?

3. Modified Hachinski ischemic score?4?

4. Young Mania Rating Scale>11(Young, Biggs, Ziegler, & Meyer, 1978);

5. Any suicidal tendencies in recent 2 years;

6. Cornell Scale for Depression and Dementia?10;

7. Familial AD;

8. Abnormal brain structural magnetic resonance imaging (MRI) scan, including
hydrocephalus, stroke, structural lesions, etc. that would potentially confound the

9. Surgical history of the central nervous system;

10. Severe cardiovascular/pulmonary disorders.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557